Refuge Biotech is a discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy. Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) through their receptor-dCas platform to develop therapeutic cells that are programmed to make cancer-fighting decisions inside the patient's body.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/02/18 | $25,000,000 | Series B |
3E Bioventures 3SBio  Ocean Pine Healthcare Fund Sangel Capital ShangBay Capital WuXi Healthcare Ventures | undisclosed |
